| Supporting Unit | Leader |
| Unit for Education and Academic Events | Visiting Prof. Thiago Carvalho |
Research Divisions, Labs & Researchers
Department of Immunology and Genomic Medicine
Our laboratory was the global pioneer in advocating PD-1 antibody-based cancer immunotherapy. Achieving a better understanding of the fundamental biology behind checkpoint inhibitors in human cancer models will help us to build better therapy regimes and enhance the efficiency and effectivity of cancer immunotherapy.
top
Department of Immune Metabolism
We are focusing on metabolites as regulators of homeostasis, aging, and immune system, and aim to identify their target proteins and elucidate their mechanisms of actions, with the goal of developing novel therapies for immune diseases and advancing innovations in cancer immunotherapy.
top
Division of Integrated High-Order Regulatory Systems
Our goal is to build the basic tools for future immune system intervention in cancer and other diseases through research on immune system interactions in health and disease, using advanced proteomics and metabolomics tools.
top
Division of Cancer Immune Multicellular System Regulation
We are developing unique analytical methods for studying the tumor microenvironment to comprehensively analyze interactions between the immune system and cancer cells. By establishing the concept that genetic abnormalities in cancer cells directly affect immune responses, we are pioneering a new field in tumor biology.
top
Division of Clinical Immunology and Cancer Immunotherapy
We use immune adverse events in cancer immunotherapy together with bio-makers as model systems to better understand and predict the likelihood of success as well as risk factors of cancer immunotherapy in various types of cancer.
top
Division of Cancer Immunotherapy
Our goal is to develop next generation cancer immunotherapies that enhance the efficacy of PD-1 blockade. We will maximize immune activation at tumor sites using a two sided approach, i.e. unique innate immunity-activating adjuvant and enhanced tumor destruction.
top
Division of Clinical Pharmacology and Cancer Immunotherapy
We are at the forefront of pioneering research and development in new molecular targeted therapies and immunotherapies that focus on the vulnerabilities arising from genetic alterations in cancer cells. Our mission is to develop effective and safe treatments tailored to individual patients.
top
Multi-Omics Platform
Together with our collaborators at Kyoto University and in industry, we have been building a powerful new multi-omics platform to accelerate research into interactions between cancer and the immune system. This platform is available to all scientists at CCII and Kyoto University.
top
Informatics Platform
Our platform advances and supports cancer immunology research by conducting in-silico analysis of quantitative data obtained from various devices, including high-throughput sequencers.
top
Specially Appointed Professors
CCII is hosting scientists from Kyoto University, other national research institutions, industry or overseas research organizations with access to CCII’s special facilities and collaborative space.
top
Visiting Professors
Our goal at CCII is to work closely with organizations in academia and industry in Japan and abroad. Already today, CCII is hosting numerous of scientists from industry or overseas research organizations in visiting positions. CCII’s new research building is providing special facilities for visiting scientists.
top
Akio Ohta
